Lou Kennedy Is Out as CEO of Nephron Pharmaceuticals

Columbia, SC, October 16, 2026 —

Lou Kennedy is out as chief executive officer of Nephron Pharmaceuticals, the company she led through its relocation to South Carolina. The available information confirms the leadership change and Kennedy’s role during the relocation, but does not specify when she left the position or what prompted the change.

Details about who, if anyone, has taken over as CEO were not provided. The information also does not identify Kennedy’s next role or say whether she will remain involved with the company in another capacity.

Kennedy led Nephron through its move to South Carolina, but no timeline, starting location or further details about the relocation were provided. The available account does not describe the company’s current operations or explain how the CEO change may affect them.

Nephron Pharmaceuticals’ announcement or additional comment was not included in the information available for this report. As a result, the reason for Kennedy’s departure, the timing of the transition and any plans for the company’s leadership remain unclear. No further details about the circumstances surrounding the change were provided.

The reported transition marks a change in the company’s top executive role. Beyond Kennedy’s departure and her leadership during Nephron’s relocation to South Carolina, the available information does not establish what comes next for the company or for Kennedy.

Story summarized from the original created by Google News on news.google.com, see more information here.